Aethlon Medical, Inc. (OTCMKTS:AEMD) Slowing Down

[[tagnumber 0]][[tagnumber 1]]We have seen an increased interest in certain companies since the Ebola outbreak. One of them is Aethlon Medical, Inc. (OTCMKTS:AEMD) and what sets it apart from the competition is that they have a product that has so far shown positive results.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The interest in [[tagnumber 6]]AEMD [[tagnumber 7]]started in October when it was announced that a Ugandan physician who was treating Ebola patients in Serra Leone had contracted the virus and was receiving treatment in the Frankfurt University Hospital. [[tagnumber 6]]AEMD’s [[tagnumber 7]]Hemopurifier® was part of the treatment and everyone was very excited about the results, which was also visible in the company’s stock charts.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]And although [[tagnumber 6]]AEMD [[tagnumber 7]]isn’t in a very strong financial situation the company still manages to currently command a highly overpriced market cap of $172 million. Let’s see what the company recorded in their books for the third quarter of the year.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 18]][[tagnumber 19]][[tagnumber 2]] [[tagnumber 21]] [[tagnumber 22]]cash: $526 thousand[[tagnumber 23]] [[tagnumber 22]]current assets: $892 thousand[[tagnumber 23]] [[tagnumber 22]]total assets: $1 million[[tagnumber 23]] [[tagnumber 22]]current liabilities: $3.38 million[[tagnumber 23]] [[tagnumber 22]]total liabilities: $4.37 million[[tagnumber 23]] [[tagnumber 22]]quarterly revenues: $479 thousand[[tagnumber 23]] [[tagnumber 22]]operating loss: $601 thousand[[tagnumber 23]] [[tagnumber 36]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Furthermore, there is the issue with the convertible notes that have a highly discounted conversion price, as well as the massive 16 million shares issued at $0.042 and the 3.5 million that were issued at the same price through conversion of notes, things of which we wrote in our previous article.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]In most recent news, the Ugandan doctor that was being treated in Frankfurt has already been discharged from the hospital with no signs of Ebola. Yesterday, the company also announced that it has made its first shipment of 4 Hemopurifier® units is on its way to the Biocontainment Unit at the Nebraska Medical Center.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Still, there is time until we see further success, because the ebola treatment is surely not going to be able to keep the company afloat. Statistically 6 out of 10 patients and the total amount of people that have died from Ebola since June, 2014 is 5000, while for comparison more than 500 thousand people die each year from the common flu and more than 1 million die from malaria.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]There is, however, light in the tunnel as the Hemopurifier® treatment is versatile and [[tagnumber 6]]AEMD [[tagnumber 7]]will soon begin their first clinical studies of its effects not only on Ebola, but on HIV and Hepatitis C after it received and FDA approval for an Investigational Device Exemption.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]However, how long will the hype continue. Yesterday’s session [[tagnumber 6]]AEMD [[tagnumber 7]]dropped 9.08% in value and closed at $0.5155. The amount of shares that was traded was significantly lower than that of the previous day, but the 19.47 million that changed their owners still managed to generate a significant daily dollar volume of $10.31 million.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Things are certainly beginning to look shaky, considering the current market cap and the fundamentals that [[tagnumber 6]]AEMD [[tagnumber 7]]has to show. This is surely reason enough for you to do your due diligence and carefully weigh out the risks before putting any money on the line.[[tagnumber 2]]